Using Pulmicort (Budesonide) for Nasal Rinses
Pulmicort Respules can be used off-label for nasal irrigation in chronic rhinosinusitis, though this is not an FDA-approved indication—the medication is only approved for nebulized inhalation therapy for asthma. 1
FDA-Approved Use vs. Off-Label Practice
The FDA labeling for Pulmicort Respules explicitly states it should be administered via jet nebulizer with a mouthpiece or face mask for asthma treatment, and that "the effects of mixing PULMICORT RESPULES with other nebulizable medications have not been adequately assessed." 1 However, clinical practice has evolved to include off-label use in nasal irrigation for chronic rhinosinusitis.
Evidence Supporting Nasal Irrigation Use
Despite the lack of FDA approval for this indication, multiple studies demonstrate efficacy and general safety when budesonide respules are mixed with saline for nasal irrigation:
For chronic rhinosinusitis with nasal polyps, budesonide nasal irrigation (1 mg twice daily via transnasal nebulization) significantly improved nasal obstruction scores (from 8.4 to 4.0, p<0.01) and reduced polyp size more effectively than standard budesonide nasal spray. 2
For allergic rhinitis, adding budesonide respules to buffered hypertonic saline irrigation produced significantly better improvement in SNOT-22 scores (p=0.012) and VAS scores (p=0.007) compared to saline irrigation alone. 3
Post-endoscopic sinus surgery, budesonide irrigation improved symptom scores and mucosal healing compared to standard nasal sprays, with better penetration into sinus cavities. 4, 5
Critical Safety Considerations
Long-term use (>6 months) of budesonide nasal irrigations carries a risk of asymptomatic hypothalamic-pituitary-adrenal axis (HPA) suppression in 23% of patients. 6
Key Safety Points:
Concomitant use of nasal steroid sprays AND pulmonary steroid inhalers while using daily budesonide irrigations significantly increases the risk of HPA suppression (p=0.024). 6
Morning serum cortisol decreased from 17.6 to 14.8 μg/dL after one week of treatment, though values remained within normal range (5-25 μg/dL). 2
Most patients with HPA suppression were asymptomatic and could continue therapy under endocrinology supervision. 6
Patients who discontinued budesonide for one month showed return to near-normal cortisol levels. 6
Clinical Guideline Context
Current guidelines for chronic rhinosinusitis with nasal polyposis recognize intranasal corticosteroids delivered via multiple modalities including "rinse (also called flush or irrigation)" as appropriate treatment options. 7 The 2023 Joint Task Force guidelines specifically acknowledge nasal rinses as a valid delivery method for intranasal corticosteroids in this population. 7
Practical Recommendations
If using budesonide respules for nasal irrigation:
Typical dosing is 0.5-1 mg mixed with saline irrigation solution once or twice daily 2, 3
Monitor for HPA axis suppression if treatment extends beyond 6 months, particularly in patients using other corticosteroid formulations concurrently 6
Consider baseline and follow-up cortisol testing for long-term users 6
Avoid combining with both nasal steroid sprays and inhaled corticosteroids when possible 6
Patients should rinse their mouth after use to reduce oral candidiasis risk, as recommended for the approved inhalation use 1